Brazil, Mexico lead Medical Revolution in Latin America

Last updated on March 13th, 2023 at 06:15 am

Brazil and Mexico are at the forefront of a medical revolution taking place in Latin America. Manufacturers of in-vitro diagnostics (IVD) goods and services are growing more and more interested in the Latin American IVD market. Latin American nations offer IVD companies a multi-billion dollar potential with a projected compound annual growth rate (CAGR) of 2.4% between 2022 and 2027.

The two most populous nations in Latin America, Brazil and Mexico, which together account for more than half of the region’s total population of 646 million people and exceed 340 million, are the main forces behind this medical revolution.

The Latin American IVD market is expanding as a result of population expansion, government insurance, newly insured patients, growing technology, and modernized healthcare facilities. A major portion of the population is getting older, which has an effect on population growth overall.

Keep Reading

Although the IVD market in Latin America is expanding, different nations in the region use IVD testing differently. With sales expected to reach $1 billion in 2022, Brazil will be the region’s largest IVD market, followed by Mexico, which will have IVD sales of about $800 million. Peru, Chile, and Colombia are also showing consistent growth.

The South American IVD market still faces several obstacles. They include different laws governing sales, payment procedures, location, marketing techniques, and logistical problems. While formulating plans to join the Latin American market, IVD enterprises should keep this in mind.

For producers, the Latin American IVD market holds a lot of promise. IVD organizations can create effective strategies for breaking into this expanding industry by taking into account the various elements and difficulties. Because of their leadership in this medical revolution, Brazil and Mexico present the greatest possibility for IVD businesses. Several regions of South America would soon experience the medical revolution.

In addition, Bolivia has opened its El Alto Preclinical Radiopharmacy Cyclotron Complex, which will create Fluorodeoxyglucose (FDG) radiopharmaceuticals to be utilized in the treatment of cancer patients, marking a historic milestone for the country.

Also Read

;- Xi Jinping begins precedent-busting third term as China’s president

Staff Writer

Politics, diplomatic developments and human stories are what keep me grounded and more aligned to bring the best news to all readers.

Recent Posts

Why UK Film Students Are Studying Cary-Hiroyuki Tagawa’s Acting Techniques

Global film legends are being used by British film schools to redefine the manner in which future actors train their… Read More

December 5, 2025

Aviation Bottlenecks: Edinburgh Airport, Why it Became a Case Study in 2025

When the rise in customer numbers was met with low capacity to carry them, Edinburgh Airport became a high-profile symbol… Read More

December 5, 2025

World Health Organization Unveils 2026 Guidelines on New Obesity Medicines

The World Health Organization (WHO) has released its first global guidelines for the use of new obesity medicines, marking a… Read More

December 5, 2025

Military Demand vs. Renewable Future: The Global Rush for Critical Minerals — Can Climate & Security Co-exist?

The global race for critical minerals has intensified as countries push toward clean energy while simultaneously expanding military capabilities. Lithium,… Read More

December 5, 2025

Sustainability vs Fast Fashion: Why the Fashion Industry’s Environmental & Labour Impact Still Matters

The entertainment around the global fashion industry is facing increased scrutiny as the consumers get to know more about the… Read More

December 5, 2025

Hotel Deals & Travel Discounts in Japan: What Japan’s ‘GoGo Sale’ Means for Holiday-Season Bookers

The GoGo Sale of Japan is aimed at stimulating domestic and inbound tourism by offering time-promotion discounts on hotels, transport,… Read More

December 5, 2025

This website uses cookies.

Read More